Renal cell carcinoma bone metastases: clinical advances.

Abstract

Bone is a common site of metastatic spread in patients with advanced renal cell carcinoma (RCC) occurring in around one-third of patients enrolled in clinical trials evaluating modern systemic therapies for this disease. Until recently, limited systemic therapeutic options were available for advanced RCC. Nowadays, a quiver of agents have demonstrated activity, including compounds targeting the vascular endothelial growth factor (VEGF) axis and those targeting the mammalian target of rapamycin (mTOR). Despite a detailed biological understanding of how these drugs work, their effect on bony metastases is less clear. Data suggesting that bisphosphonates (namely zoledronic acid) benefit patients with bone metastases from advanced RCC was gathered prior to the targeted therapy era; therefore, there is some uncertainty about their role in patients on modern RCC therapies. This review summarizes the current targeted therapies registered for use in advanced RCC and postulates how some of them might affect the behavior of bone metastases. It also explores the data available on the role of bisphosphonates for bone metastases from RCC, describes methods of assessing response to therapy for bone metastases and delineates future expectations for the treatment of bone metastases from advanced RCC.

• Authors: Chakshu Sahi, Jennifer J Knox, Mark Clemons, Anthony M Joshua, Reuben Broom
• Journal: Therapeutic advances in medical oncology (Ther Adv Med Oncol) Vol. 2 Issue 2 Pg. 75-83 (Mar 2010) ISSN: 1758-8359 [Electronic] England
• PMID: 21789128 (Publication Type: Journal Article)